Bullet flag-united-kingdom flag-ireland


  • Respiratory

Inhaler Switching Approaches in Asthma and COPD: What Factors to Consider?

In 2019, the NHS became the first healthcare system to commit to reaching net zero carbon emissions.1 Whilst the commitment to become net zero is extremely positive, achieving sustainable healthcare without compromising patient care requires careful thought and consideration. One of the key strategies to help achieve a “net zero NHS” has been to reduce the use of pressurised metered dose inhalers (pMDIs) and replacing these with lower carbon footprint inhalers such as dry powder inhalers (DPIs), wherever appropriate.

Currently, different approaches are being used to switch patients from pMDIs to DPIs, which can have varying consequences on patient care. In this on-demand webinar Prof Omar Usmani provides a critical review of the different approaches to inhaler device switching and its potential consequences on patient care.

1. NHS Long Term Plan. Available at https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf

We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.

Professor Omar Usmani

Professor Omar Usmani is a Group Leader of the Clinical Research Group within the Airway Disease Section at the National Heart and Lung Institute (NHLI) and a Principal Investigator. He is a professor in Respiratory Medicine and Consultant Physician at the NHLI, Imperial College London and Royal Brompton Hospital (RBH). Professor Usmani is also the Co-Director of Imperial’s Network of Excellence in Aerosols and Health, established in 2021.

Professor Omar Usmani has given keynote lectures at prestigious international scientific meetings and written state of the art reviews as a leading expert about the future of inhalation medicine on ERS Vision. He has also pioneered novel and sophisticated techniques of assessing inhaled drug delivery, detecting dysfunction of small airways physiology, and characterising airflow heterogeneity using pulmonary imaging to understand structure-function treatment relationships within the lungs.